Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [19]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-83077 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-83077, RRID:AB_11039909
- Product name
- Rabbit Polyclonal ATRX Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Specificity of human ATRX antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
ATRX represses alternative lengthening of telomeres.
Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Altered telomeres in tumors with ATRX and DAXX mutations.
The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR
Journal of neuro-oncology 2019 May;142(3):435-444
Journal of neuro-oncology 2019 May;142(3):435-444
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Li X, Oh S, Song H, Shin S, Zhang B, Freeman WM, Janknecht R
Oncology letters 2018 Nov;16(5):6652-6662
Oncology letters 2018 Nov;16(5):6652-6662
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British journal of cancer 2015 Oct 20;113(8):1244-8
British journal of cancer 2015 Oct 20;113(8):1244-8
ATRX represses alternative lengthening of telomeres.
Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, Reddel RR
Oncotarget 2015 Jun 30;6(18):16543-58
Oncotarget 2015 Jun 30;6(18):16543-58
Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.
Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K
Oncotarget 2015 Jun 30;6(18):15871-81
Oncotarget 2015 Jun 30;6(18):15871-81
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D'Andrea K, Merrill S, Cho NW, Greenberg RA, Else T, Montone K, LiVolsi V, Fraker D, Daber R, Cohen DL, Nathanson KL
Nature communications 2015 Jan 21;6:6140
Nature communications 2015 Jan 21;6:6140
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH
Oncotarget 2014 Sep 30;5(18):8083-92
Oncotarget 2014 Sep 30;5(18):8083-92
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Haberler C, Wöhrer A
Clinical neuropathology 2014 Mar-Apr;33(2):108-11
Clinical neuropathology 2014 Mar-Apr;33(2):108-11
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Haberler C, Wöhrer A
Clinical neuropathology 2014 Mar-Apr;33(2):108-11
Clinical neuropathology 2014 Mar-Apr;33(2):108-11
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Mar 10;32(8):783-90
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Mar 10;32(8):783-90
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li XN, Van Meter T, Dirks PB, Rutka JT, Taylor MD, Tabori U, Hawkins C
Acta neuropathologica 2014 Dec;128(6):863-77
Acta neuropathologica 2014 Dec;128(6):863-77
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, Perry A
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013 Nov;26(11):1425-32
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013 Nov;26(11):1425-32
Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ
Brain pathology (Zurich, Switzerland) 2013 May;23(3):237-43
Brain pathology (Zurich, Switzerland) 2013 May;23(3):237-43
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK, ALT Starr Cancer Consortium.
PLoS genetics 2012;8(7):e1002772
PLoS genetics 2012;8(7):e1002772
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H
Oncotarget 2012 Jul;3(7):709-22
Oncotarget 2012 Jul;3(7):709-22
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 Jul;25(7):1033-9
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 Jul;25(7):1033-9
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N
Nature 2012 Jan 29;482(7384):226-31
Nature 2012 Jan 29;482(7384):226-31
Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK
Science (New York, N.Y.) 2011 Jul 22;333(6041):425
Science (New York, N.Y.) 2011 Jul 22;333(6041):425
The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Bolander A, Agnarsdóttir M, Strömberg S, Ponten F, Hesselius P, Uhlen M, Bergqvist M
Cancer genomics & proteomics 2008 Nov-Dec;5(6):293-300
Cancer genomics & proteomics 2008 Nov-Dec;5(6):293-300
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: ATRX Antibody [NBP1-83077] - Analysis in A-549 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using anti-ATRX antibody. Remaining relative intensity is presented. Loading control: anti-GAPDH.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATRX Antibody [NBP1-83077] - Staining of human cerebral cortex shows moderate nuclear positivity in neurons and glial cells.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATRX Antibody [NBP1-83077] - Staining of human glioma shows moderate to strong nuclear positivity in tumor cells.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATRX Antibody [NBP1-83077] - Staining of human liver shows no positivity in hepatocytes as expected.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATRX Antibody [NBP1-83077] - Staining of human uterine cervix shows moderate to strong nuclear positivity in squamous epithelial cells.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATRX Antibody [NBP1-83077] - Staining in human cerebral cortex and liver tissues . Corresponding ATRX RNA-seq data are presented for the same tissues.
